ciprofloxacin has been researched along with Pouchitis in 42 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Pouchitis: Acute INFLAMMATION in the INTESTINAL MUCOSA of the continent ileal reservoir (or pouch) in patients who have undergone ILEOSTOMY and restorative proctocolectomy (PROCTOCOLECTOMY, RESTORATIVE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combination therapy with ciprofloxacin and tinidazole was generally well tolerated and was effective in treating patients with chronic refractory pouchitis." | 9.12 | Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. ( Bennett, AE; Brzezinski, A; Fazio, VW; Lashner, BA; Lopez, R; Oikonomou, I; Remzi, FH; Shen, B; Sherman, KK, 2007) |
| "The fecal flora obtained from 13 patients with ulcerative colitis was examined at the beginning of a pouchitis episode before treatment, during treatment with metronidazole or ciprofloxacin, and during pouchitis-free periods." | 9.11 | Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. ( Gosselink, MP; Hop, WC; Laman, JD; Ruseler-van Embden, JG; Schouten, WR; van Lieshout, LM, 2004) |
| "Four-week treatment with a combination of metronidazole and ciprofloxacin is highly effective in patients with active recurrent or refractory pouchitis, objectively improving the inflammation and quality of life." | 9.10 | Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. ( Campieri, M; Gionchetti, P; Helwig, U; Kamm, MA; Mimura, T; Nicholls, RJ; Poggioli, G; Rizzello, F; Schreiber, S; Talbot, IC, 2002) |
| "Metronidazole is effective for the treatment of acute pouchitis after ileal pouch-anal anastomosis, but it has not been directly compared with other antibiotics." | 9.09 | A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. ( Achkar, JP; Bambrick, ML; Bevins, CL; Brzezinski, A; Fazio, VW; Lashner, BA; Ormsby, AH; Remzi, FH; Seidner, DL; Shen, B, 2001) |
| "In this retrospective cohort study, we demonstrated no significant difference in the real-world effectiveness of ciprofloxacin, metronidazole, or combination therapy for the initial episode of pouchitis." | 8.31 | The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study. ( Barnes, EL; Desai, A; Kochhar, GS, 2023) |
| "Oral antibiotics, such as ciprofloxacin (CFX), are widely used for the treatment of acute and chronic pouchitis." | 7.96 | Increased Quinolone-Resistant Mutations of gyrA and parC Genes after Pouchitis Treatment with Ciprofloxacin. ( Fukushima, K; Kohyama, A; Saito, T; Watanabe, K, 2020) |
| "Release of hydrogen sulfide when pouchitis was active (6." | 7.73 | Association between fecal hydrogen sulfide production and pouchitis. ( Furne, JK; Levitt, MD; Madoff, RD; Ohge, H; Rothenberger, DA; Springfield, J, 2005) |
| "Rifaximin-ciprofloxacin combination therapy is safe and objectively effective in chronic active refractory pouchitis and may salvage a significant percentage of 'at risk pouches'." | 7.73 | Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. ( Abdelrazeq, AS; Kelly, SM; Leveson, SH; Lund, JN, 2005) |
| " Acute pouchitis: One study compared ciprofloxacin with metronidazole." | 5.41 | Systematic review and meta-analysis of randomised controlled trials: Medical therapies for the treatment and prevention of pouchitis. ( Alphonsus, L; Beaton, M; Bessissow, T; De Silva, TA; Hanzel, J; Jairath, V; Kayal, M; Ma, C; MacDonald, JK; Sedano, R; Singh, S, 2023) |
| "Combination therapy with ciprofloxacin and tinidazole was generally well tolerated and was effective in treating patients with chronic refractory pouchitis." | 5.12 | Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. ( Bennett, AE; Brzezinski, A; Fazio, VW; Lashner, BA; Lopez, R; Oikonomou, I; Remzi, FH; Shen, B; Sherman, KK, 2007) |
| "The fecal flora obtained from 13 patients with ulcerative colitis was examined at the beginning of a pouchitis episode before treatment, during treatment with metronidazole or ciprofloxacin, and during pouchitis-free periods." | 5.11 | Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. ( Gosselink, MP; Hop, WC; Laman, JD; Ruseler-van Embden, JG; Schouten, WR; van Lieshout, LM, 2004) |
| "Patients with pouchitis at least twice in the previous year or requiring continuous antibiotics, associated with a pouchitis disease activity index (PDAI) > or =7 (0 = perfect; 18 = worst), in whom remission was induced by four weeks of combined metronidazole and ciprofloxacin, were randomised to receive VSL#3 6 g or placebo once daily for one year or until relapse." | 5.11 | Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. ( Campieri, M; Gionchetti, P; Helwig, U; Kamm, MA; Mimura, T; Nicholls, RJ; Poggioli, G; Rizzello, F; Schreiber, S; Talbot, IC, 2004) |
| "Four-week treatment with a combination of metronidazole and ciprofloxacin is highly effective in patients with active recurrent or refractory pouchitis, objectively improving the inflammation and quality of life." | 5.10 | Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. ( Campieri, M; Gionchetti, P; Helwig, U; Kamm, MA; Mimura, T; Nicholls, RJ; Poggioli, G; Rizzello, F; Schreiber, S; Talbot, IC, 2002) |
| "Metronidazole is effective for the treatment of acute pouchitis after ileal pouch-anal anastomosis, but it has not been directly compared with other antibiotics." | 5.09 | A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. ( Achkar, JP; Bambrick, ML; Bevins, CL; Brzezinski, A; Fazio, VW; Lashner, BA; Ormsby, AH; Remzi, FH; Seidner, DL; Shen, B, 2001) |
| "For acute pouchitis, very low quality evidence suggests that ciprofloxacin may be more effective than metronidazole." | 4.91 | Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. ( Holubar, SD; Pardi, DS; Sandborn, WJ; Singh, S; Stroud, AM, 2015) |
| " For the treatment of acute pouchitis (4 RCTS, 5 agents), ciprofloxacin was more effective at inducing remission than metronidazole." | 4.86 | Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. ( Cima, RR; Holubar, SD; Pardi, DS; Sandborn, WJ, 2010) |
| "In this retrospective cohort study, we demonstrated no significant difference in the real-world effectiveness of ciprofloxacin, metronidazole, or combination therapy for the initial episode of pouchitis." | 4.31 | The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study. ( Barnes, EL; Desai, A; Kochhar, GS, 2023) |
| "5%) used antibiotics for pouchitis, predominantly ciprofloxacin." | 4.12 | Long-term Antibiotic Treatment in Pouchitis-Patterns of Use and Safety. ( Avraham, Y; Banon, L; Bar, N; Cohen, NA; Dotan, I; Dubinsky, V; Gophna, U; Maharshak, N; Tulchinsky, H; Weiss, GA, 2022) |
| "Oral antibiotics, such as ciprofloxacin (CFX), are widely used for the treatment of acute and chronic pouchitis." | 3.96 | Increased Quinolone-Resistant Mutations of gyrA and parC Genes after Pouchitis Treatment with Ciprofloxacin. ( Fukushima, K; Kohyama, A; Saito, T; Watanabe, K, 2020) |
| "The concept that the gut microbiota plays a major role in the development of pouchitis in ulcerative colitis patients after restorative proctocolectomy with ileal pouch-anal anastomosis, is widely accepted and supported by a widespread use of some antibiotics (metronidazole and/or ciprofloxacin, rifaximin) to treat this condition." | 3.80 | Role of probiotics in the management of pouchitis. ( Guslandi, M, 2014) |
| "Fourteen consecutive patients with symptomatic pre-pouch ileitis were treated with ciprofloxacin 500 mg b." | 3.75 | An open study of antibiotics for the treatment of pre-pouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis. ( Bell, AJ; Ciclitira, PJ; Clark, SK; McLaughlin, SD; Nicholls, RJ; Tekkis, PP, 2009) |
| "Rifaximin-ciprofloxacin combination therapy is safe and objectively effective in chronic active refractory pouchitis and may salvage a significant percentage of 'at risk pouches'." | 3.73 | Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. ( Abdelrazeq, AS; Kelly, SM; Leveson, SH; Lund, JN, 2005) |
| "Release of hydrogen sulfide when pouchitis was active (6." | 3.73 | Association between fecal hydrogen sulfide production and pouchitis. ( Furne, JK; Levitt, MD; Madoff, RD; Ohge, H; Rothenberger, DA; Springfield, J, 2005) |
| "A combination of rifaximin and ciprofloxacin was effective in patients with active chronic, treatment-resistant pouchitis, suggesting the need, in these patients, for treatment using antibiotic agents with wide antibacterial spectrum of activity." | 3.70 | Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. ( Brigidi, P; Campieri, M; Ferrieri, A; Gionchetti, P; Johansson, R; Poggioli, G; Rizzello, F; Rossi, M; Ugolini, F; Venturi, A, 1999) |
| "Approximately half the patients with ulcerative colitis who undergo restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) will subsequently have pouchitis, and among those patients, one fifth will have chronic pouchitis." | 3.30 | Vedolizumab for the Treatment of Chronic Pouchitis. ( Bressler, B; Danese, S; Escher, A; Feagan, BG; Ferrante, M; Gionchetti, P; Hart, A; Jairath, V; Jones, S; Lindner, D; Löwenberg, M; Shen, B; Silverberg, MS; Travis, S, 2023) |
| "Patients with pouchitis have a wide range of symptoms, endoscopic and histologic features, disease course, and prognosis." | 2.61 | Prevention and Medical Treatment of Pouchitis In Ulcerative Colitis. ( Benlice, C; Shen, B; Steele, SR, 2019) |
| "Four studies assessed treatment of acute pouchitis." | 2.61 | Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. ( Holubar, SD; Nguyen, N; Pardi, DS; Singh, S; Zhang, B, 2019) |
| "Pouchitis is the most frequent long-term complication of IPAA in patients with UC, with a cumulative prevalence of up to 50%." | 2.46 | Diagnosis and management of pouchitis and ileoanal pouch dysfunction. ( Navaneethan, U; Shen, B, 2010) |
| "Pouchitis is a common and long-term complication of ileal pouch-anal anastomosis in patients with underlying ulcerative colitis." | 2.43 | [Diagnosis and medical treatment of pouchitis in ileal pouch-anal anastomosis in patients with ulcerative colitis]. ( Fujii, T; Kawamata, S; Matsushita, M; Okazaki, K; Shimatani, M, 2005) |
| "This article reviews the possible treatments for pouchitis, focusing especially on treatment with probiotics, which seem to be a new and promising alternative to antibiotics." | 2.43 | [Probiotics--should we change the treatment strategy for pouchitis?]. ( Kjeldsen, J; Klinge, LG, 2006) |
| "In general, patients with Crohn's disease are not usually offered IPAA, because recurrence of disease, fistulas, abscesses, and strictures may lead to a higher incidence of pouch failure." | 2.41 | Complications after ileal pouch-anal anastomosis. ( Lichtenstein, GR; Stein, RB, 2000) |
| "The elective treatment for acute pouchitis is antibiotics." | 1.56 | Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. ( Barreiro-de Acosta, M; Beltrán, B; Chaparro, M; Espín, E; Ferrer Bradley, I; Gisbert, JP; Guarner, F; Gutiérrez, A; Marín-Jimenez, I; Nos, P; Rodríguez-Lago, I, 2020) |
| "Some patients have recurrence of flares, or become antibiotic-dependent, and require repeated courses or prolonged periods of antibiotic therapy." | 1.56 | Predominantly Antibiotic-resistant Intestinal Microbiome Persists in Patients With Pouchitis Who Respond to Antibiotic Therapy. ( Bar, N; Dotan, I; Dubinsky, V; Godny, L; Golan, N; Gophna, U; Keizer, D; Rabinowitz, K; Reshef, L; Tulchinsky, H; Yadgar, K; Zonensain, K, 2020) |
| "Four studies assessed treatment of acute pouchitis." | 1.51 | Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. ( Holubar, SD; Nguyen, N; Pardi, DS; Singh, S; Zhang, B, 2019) |
| "Pouchitis was classified as acute or chronic pouchitis." | 1.39 | Clinical features and management of pouchitis in Japanese ulcerative colitis patients. ( Bando, T; Ikeuchi, H; Matsuoka, H; Takesue, Y; Tomita, N; Uchino, M, 2013) |
| "Pouchitis is the most common long-term complication after restorative total proctocolectomy and IPAA for ulcerative colitis." | 1.38 | The long-term clinical course of pouchitis after total proctocolectomy and IPAA for ulcerative colitis. ( Funayama, Y; Haneda, S; Ogawa, H; Sasaki, I; Shibata, C; Suzuki, H; Takahashi, K; Watanabe, K, 2012) |
| "The incidence of PPI in patients with ulcerative colitis/indeterminate colitis is 5." | 1.35 | Incidence and short-term implications of prepouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. ( Bell, AJ; Ciclitira, PJ; Clark, SK; McLaughlin, SD; Nicholls, RJ; Tekkis, PP, 2009) |
| "Pouchitis is the most common long-term sequela of ileal pouch-anal anastomosis (IPAA) following total proctocolectomy." | 1.33 | Clostridium difficile-associated pouchitis. ( Bennett, AE; Fazio, VW; Goldblum, JR; Hull, TL; Remzi, FH; Shen, B, 2006) |
| "Collagenous colitis is characterised by watery diarrhoea, normal colonic mucosa on endoscopy, diffuse colitis with surface epithelial injury, and a distinctive thickening of the subepithelial collagen table on histology." | 1.33 | Collagenous pouchitis. ( Bennett, AE; Fazio, VW; Lashner, BA; Remzi, FH; Shen, B; Sherman, KK; Sun, J, 2006) |
| "Pouchitis is often diagnosed based on symptoms and empirically treated with antibiotics (treat-first strategy)." | 1.32 | A cost-effectiveness analysis of diagnostic strategies for symptomatic patients with ileal pouch-anal anastomosis. ( Achkar, JP; Bambrick, ML; Bevins, CL; Brzezinski, A; Fazio, VW; Lashner, BA; Remzi, FH; Shen, B; Shermock, KM, 2003) |
| "Pouchitis is the major long-term complication after ileal pouch-anal anastomosis (IPAA) in patients operated on for ulcerative colitis." | 1.32 | CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue. ( Baggiolini, M; Campieri, M; Gionchetti, P; Helwig, U; Kühbacher, T; Lammers, K; Rizzello, F; Schreiber, S; Uguccioni, M, 2004) |
| "The medical treatment of acute pouchitis was usually oral metronidazole (250 mg twice daily) for 2 weeks or oral ciprofloxacin (200 mg thrice daily) in patients who could not tolerate metronidazole." | 1.32 | Incidence and therapeutic outcome of pouchitis for ulcerative colitis in Japanese patients. ( Ikeuchi, H; Nakamura, M; Nakano, H; Noda, M; Uchino, M; Yamamura, T; Yanagi, H, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.38) | 18.2507 |
| 2000's | 20 (47.62) | 29.6817 |
| 2010's | 13 (30.95) | 24.3611 |
| 2020's | 8 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Bar, N | 2 |
| Avraham, Y | 1 |
| Dubinsky, V | 2 |
| Cohen, NA | 1 |
| Weiss, GA | 1 |
| Banon, L | 1 |
| Tulchinsky, H | 2 |
| Maharshak, N | 1 |
| Gophna, U | 2 |
| Dotan, I | 2 |
| Travis, S | 1 |
| Silverberg, MS | 1 |
| Danese, S | 2 |
| Gionchetti, P | 6 |
| Löwenberg, M | 1 |
| Jairath, V | 2 |
| Feagan, BG | 1 |
| Bressler, B | 1 |
| Ferrante, M | 1 |
| Hart, A | 1 |
| Lindner, D | 1 |
| Escher, A | 1 |
| Jones, S | 1 |
| Shen, B | 10 |
| Alphonsus, L | 1 |
| De Silva, TA | 1 |
| Ma, C | 1 |
| MacDonald, JK | 1 |
| Hanzel, J | 1 |
| Beaton, M | 1 |
| Bessissow, T | 1 |
| Kayal, M | 1 |
| Sedano, R | 1 |
| Singh, S | 4 |
| Barnes, EL | 1 |
| Desai, A | 1 |
| Kochhar, GS | 1 |
| Emile, SH | 1 |
| Horesh, N | 1 |
| Freund, MR | 1 |
| Garoufalia, Z | 1 |
| Gefen, R | 1 |
| Khan, SM | 1 |
| Silva-Alvarenga, E | 1 |
| Wexner, SD | 1 |
| Reshef, L | 1 |
| Keizer, D | 1 |
| Golan, N | 1 |
| Rabinowitz, K | 1 |
| Godny, L | 1 |
| Yadgar, K | 1 |
| Zonensain, K | 1 |
| Nguyen, N | 2 |
| Zhang, B | 2 |
| Holubar, SD | 4 |
| Pardi, DS | 5 |
| Fukushima, K | 1 |
| Saito, T | 1 |
| Kohyama, A | 1 |
| Watanabe, K | 2 |
| Barreiro-de Acosta, M | 1 |
| Marín-Jimenez, I | 1 |
| Rodríguez-Lago, I | 1 |
| Guarner, F | 1 |
| Espín, E | 1 |
| Ferrer Bradley, I | 1 |
| Gutiérrez, A | 1 |
| Beltrán, B | 1 |
| Chaparro, M | 1 |
| Gisbert, JP | 1 |
| Nos, P | 1 |
| Argollo, M | 1 |
| Kotze, PG | 1 |
| Lamonaca, L | 1 |
| Gilardi, D | 1 |
| Furfaro, F | 1 |
| Yamamoto, T | 1 |
| Benlice, C | 1 |
| Steele, SR | 1 |
| Guslandi, M | 1 |
| Stroud, AM | 1 |
| Sandborn, WJ | 3 |
| McLaughlin, SD | 2 |
| Clark, SK | 2 |
| Bell, AJ | 2 |
| Tekkis, PP | 2 |
| Ciclitira, PJ | 2 |
| Nicholls, RJ | 4 |
| He, X | 1 |
| Bennett, AE | 5 |
| Lian, L | 1 |
| Turroni, S | 1 |
| Vitali, B | 1 |
| Candela, M | 1 |
| Rizzello, F | 5 |
| Campieri, M | 5 |
| Brigidi, P | 2 |
| Cima, RR | 1 |
| Navaneethan, U | 1 |
| Suzuki, H | 1 |
| Ogawa, H | 1 |
| Shibata, C | 1 |
| Haneda, S | 1 |
| Takahashi, K | 1 |
| Funayama, Y | 1 |
| Sasaki, I | 1 |
| So, K | 1 |
| Shepherd, NA | 1 |
| Mandalia, T | 1 |
| Ahmad, T | 1 |
| Uchino, M | 2 |
| Ikeuchi, H | 2 |
| Matsuoka, H | 1 |
| Bando, T | 1 |
| Takesue, Y | 1 |
| Tomita, N | 1 |
| Marteau, P | 1 |
| Seksik, P | 1 |
| Shanahan, F | 1 |
| Helwig, U | 3 |
| Lammers, K | 1 |
| Kühbacher, T | 1 |
| Schreiber, S | 3 |
| Baggiolini, M | 1 |
| Uguccioni, M | 1 |
| Shermock, KM | 1 |
| Fazio, VW | 6 |
| Achkar, JP | 3 |
| Brzezinski, A | 4 |
| Bevins, CL | 2 |
| Bambrick, ML | 2 |
| Remzi, FH | 6 |
| Lashner, BA | 5 |
| Mimura, T | 2 |
| Poggioli, G | 3 |
| Talbot, IC | 2 |
| Kamm, MA | 2 |
| Nakano, H | 1 |
| Nakamura, M | 1 |
| Yanagi, H | 1 |
| Noda, M | 1 |
| Yamamura, T | 1 |
| Gosselink, MP | 1 |
| Schouten, WR | 1 |
| van Lieshout, LM | 1 |
| Hop, WC | 1 |
| Laman, JD | 1 |
| Ruseler-van Embden, JG | 1 |
| Abdelrazeq, AS | 1 |
| Kelly, SM | 1 |
| Lund, JN | 1 |
| Leveson, SH | 1 |
| Ohge, H | 1 |
| Furne, JK | 1 |
| Springfield, J | 1 |
| Rothenberger, DA | 1 |
| Madoff, RD | 1 |
| Levitt, MD | 1 |
| Okazaki, K | 1 |
| Matsushita, M | 1 |
| Kawamata, S | 1 |
| Shimatani, M | 1 |
| Fujii, T | 1 |
| Sherman, K | 1 |
| Sherman, KK | 2 |
| Sun, J | 1 |
| Klinge, LG | 1 |
| Kjeldsen, J | 1 |
| Goldblum, JR | 1 |
| Hull, TL | 1 |
| Lopez, R | 1 |
| Oikonomou, I | 1 |
| Venturi, A | 1 |
| Ugolini, F | 1 |
| Rossi, M | 1 |
| Johansson, R | 1 |
| Ferrieri, A | 1 |
| Stein, RB | 1 |
| Lichtenstein, GR | 1 |
| Ormsby, AH | 1 |
| Seidner, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis (PROF). The PROF Study."[NCT05938465] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2023-10-11 | Recruiting | ||
| A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis[NCT00583531] | Phase 2 | 2 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Lack of enrollment) | ||
| A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Active Pouchitis[NCT00583076] | Phase 2 | 19 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Fecal Microbiota Transplantation for the Treatment of Chronic Pouchitis[NCT03538366] | 10 participants (Actual) | Interventional | 2018-05-15 | Completed | |||
| Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome: a Randomized Double Blind Placebo Controlled Study[NCT00786123] | 40 participants (Anticipated) | Interventional | 2006-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for ciprofloxacin and Pouchitis
| Article | Year |
|---|---|
Systematic review and meta-analysis of randomised controlled trials: Medical therapies for the treatment and prevention of pouchitis.
Topics: Adult; Budesonide; Ciprofloxacin; Humans; Metronidazole; Pouchitis; Randomized Controlled Trials as | 2023 |
A Systematic Review and Meta-analysis of Randomized Clinical Trials on the Prevention and Treatment of Pouchitis after Ileoanal Pouch Anastomosis.
Topics: Anastomosis, Surgical; Ciprofloxacin; Colitis, Ulcerative; Humans; Metronidazole; Pouchitis; Proctoc | 2023 |
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Topics: Anastomosis, Surgical; Anti-Bacterial Agents; Budesonide; Ciprofloxacin; Colitis, Ulcerative; Enema; | 2019 |
Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile.
Topics: Ciprofloxacin; Colitis, Ulcerative; Humans; Metronidazole; Patient-Centered Care; Pouchitis; Practic | 2019 |
Prevention and Medical Treatment of Pouchitis In Ulcerative Colitis.
Topics: Anti-Bacterial Agents; Budesonide; Ciprofloxacin; Colitis, Ulcerative; Humans; Male; Metronidazole; | 2019 |
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Topics: Adult; Budesonide; Ciprofloxacin; Colitis, Ulcerative; Enema; Gastrointestinal Agents; Humans; Metro | 2015 |
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Topics: Adult; Ciprofloxacin; Colitis, Ulcerative; Enema; Gastrointestinal Agents; Humans; Metronidazole; Po | 2010 |
Diagnosis and management of pouchitis and ileoanal pouch dysfunction.
Topics: Adenomatous Polyposis Coli; Algorithms; Anti-Infective Agents; Antitrichomonal Agents; Ciprofloxacin | 2010 |
Manipulation of the bacterial flora in inflammatory bowel disease.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Ciprofloxacin; Enterobacteriaceae; Humans; Inflammator | 2003 |
[Diagnosis and medical treatment of pouchitis in ileal pouch-anal anastomosis in patients with ulcerative colitis].
Topics: Acute Disease; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Humans; Immunologic Factor | 2005 |
[Probiotics--should we change the treatment strategy for pouchitis?].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Evidence-Based Medicine; Humans; Metron | 2006 |
Complications after ileal pouch-anal anastomosis.
Topics: Anastomosis, Surgical; Ciprofloxacin; Colitis, Ulcerative; Crohn Disease; Humans; Male; Metronidazol | 2000 |
8 trials available for ciprofloxacin and Pouchitis
| Article | Year |
|---|---|
Vedolizumab for the Treatment of Chronic Pouchitis.
Topics: Administration, Intravenous; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Chroni | 2023 |
Antibiotics and probiotics in chronic pouchitis: a comparative proteomic approach.
Topics: Anti-Bacterial Agents; Bibliometrics; Biopsy; Chronic Disease; Ciprofloxacin; Drug Therapy, Combinat | 2010 |
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
Topics: Adult; Ciprofloxacin; Drug Therapy, Combination; Feces; Female; Humans; Male; Metronidazole; Middle | 2004 |
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
Topics: Adult; Ciprofloxacin; Drug Therapy, Combination; Feces; Female; Humans; Male; Metronidazole; Middle | 2004 |
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
Topics: Adult; Ciprofloxacin; Drug Therapy, Combination; Feces; Female; Humans; Male; Metronidazole; Middle | 2004 |
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
Topics: Adult; Ciprofloxacin; Drug Therapy, Combination; Feces; Female; Humans; Male; Metronidazole; Middle | 2004 |
Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Clostridium Infections; Clostridium perfringens; Coliti | 2004 |
Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Clostridium Infections; Clostridium perfringens; Coliti | 2004 |
Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Clostridium Infections; Clostridium perfringens; Coliti | 2004 |
Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Clostridium Infections; Clostridium perfringens; Coliti | 2004 |
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Combined Modality Therapy; Female; Follow-Up Studies; H | 2005 |
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Combined Modality Therapy; Female; Follow-Up Studies; H | 2005 |
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Combined Modality Therapy; Female; Follow-Up Studies; H | 2005 |
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Combined Modality Therapy; Female; Follow-Up Studies; H | 2005 |
Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Infective Agents; Chronic Disease; Ciprof | 2007 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Male; Metron | 2002 |
22 other studies available for ciprofloxacin and Pouchitis
| Article | Year |
|---|---|
Long-term Antibiotic Treatment in Pouchitis-Patterns of Use and Safety.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colitis, Ulcerative; Humans; Metronidazole; Pouchitis; Proctoc | 2022 |
The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colitis, Ulcerative; Humans; Male; Metronidazole; Pouchitis; P | 2023 |
Predominantly Antibiotic-resistant Intestinal Microbiome Persists in Patients With Pouchitis Who Respond to Antibiotic Therapy.
Topics: Adult; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Cytokines; Drug Resistance, Bacterial; Feces; | 2020 |
Increased Quinolone-Resistant Mutations of gyrA and parC Genes after Pouchitis Treatment with Ciprofloxacin.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Colitis, Ulcerative; DNA Gyrase; DNA | 2020 |
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment.
Topics: Acute Disease; Advisory Committees; Algorithms; Anti-Bacterial Agents; Biological Products; Budesoni | 2020 |
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Topics: Anastomosis, Surgical; Anti-Bacterial Agents; Budesonide; Ciprofloxacin; Colitis, Ulcerative; Enema; | 2019 |
Role of probiotics in the management of pouchitis.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colitis, Ulcerative; Humans; Intestines; Metronidazol | 2014 |
An open study of antibiotics for the treatment of pre-pouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis.
Topics: Adult; Anal Canal; Anastomosis, Surgical; Anti-Bacterial Agents; Ciprofloxacin; Female; Humans; Ileu | 2009 |
Incidence and short-term implications of prepouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Budesonide; Ciprofloxacin; Colitis, Ul | 2009 |
Recurrent cytomegalovirus infection in ileal pouch-anal anastomosis for ulcerative colitis.
Topics: Ciprofloxacin; Colitis, Ulcerative; Colonic Pouches; Cytomegalovirus Infections; Dietary Supplements | 2010 |
The long-term clinical course of pouchitis after total proctocolectomy and IPAA for ulcerative colitis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Colonic Pou | 2012 |
Suppurative granulomatous inflammation in the ileo-anal pouch.
Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Colitis, Ulcerative; Colonic Pouches; Female; Gr | 2013 |
Clinical features and management of pouchitis in Japanese ulcerative colitis patients.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Age of Onset; Aged; Anti-Bacterial Agents; Asian Peop | 2013 |
CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue.
Topics: Adult; Antineoplastic Agents; Chemokine CCL2; Chemokine CXCL10; Chemokines, CC; Chemokines, CXC; Cip | 2004 |
A cost-effectiveness analysis of diagnostic strategies for symptomatic patients with ileal pouch-anal anastomosis.
Topics: Aged; Anal Canal; Anastomosis, Surgical; Ciprofloxacin; Clinical Trials as Topic; Cohort Studies; Co | 2003 |
Incidence and therapeutic outcome of pouchitis for ulcerative colitis in Japanese patients.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female | 2004 |
Clinical management of pouchitis.
Topics: Adult; Anti-Infective Agents; Biopsy; Ciprofloxacin; Colitis, Ulcerative; Diagnosis, Differential; H | 2004 |
Clinical management of pouchitis.
Topics: Adult; Anti-Infective Agents; Biopsy; Ciprofloxacin; Colitis, Ulcerative; Diagnosis, Differential; H | 2004 |
Clinical management of pouchitis.
Topics: Adult; Anti-Infective Agents; Biopsy; Ciprofloxacin; Colitis, Ulcerative; Diagnosis, Differential; H | 2004 |
Clinical management of pouchitis.
Topics: Adult; Anti-Infective Agents; Biopsy; Ciprofloxacin; Colitis, Ulcerative; Diagnosis, Differential; H | 2004 |
Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, Combination; Female; Hum | 2005 |
Association between fecal hydrogen sulfide production and pouchitis.
Topics: Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Feces; Female; Humans; Hydrogen Sulfide; | 2005 |
Collagenous pouchitis.
Topics: Anal Canal; Anastomosis, Surgical; Anti-Bacterial Agents; Ciprofloxacin; Colitis, Collagenous; Endos | 2006 |
Clostridium difficile-associated pouchitis.
Topics: Anti-Infective Agents; Ciprofloxacin; Clostridioides difficile; Enterocolitis, Pseudomembranous; Hum | 2006 |
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.
Topics: Adult; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female | 1999 |
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.
Topics: Adult; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female | 1999 |
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.
Topics: Adult; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female | 1999 |
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.
Topics: Adult; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female | 1999 |